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1374Objective: Cellular and mechanical treatment to prevent heart failure each holds therapeutic promise but
together have not been reported yet. The goal of the present study was to determine whether combining a cardiac
support device with cell-based therapy could prevent adverse left ventricular remodeling, more than either
therapy alone.
Methods: The present study was completed in 2 parts. In the first part, mesenchymal stem cells were isolated
from rodent femurs and seeded on a collagen-based scaffold. In the second part, myocardial infarction was
induced in 60 rats. The 24 survivors were randomly assigned to 1 of 4 groups: control, stem cell therapy, cardiac
support device, and a combination of stem cell therapy and cardiac support device. Left ventricular function was
measured with biweekly echocardiography, followed by end-of-life histopathologic analysis at 6 weeks.
Results:After myocardial infarction and treatment intervention, the ejection fraction remained preserved (74.9-
80.2%) in the combination group at an early point (2 weeks) compared with the control group (66.2-82.8%). By
6 weeks, the combination therapy group had a significantly greater fractional area of change compared with the
control group (69.2%  6.7% and 49.5%  6.1% respectively, P ¼ .03). Also, at 6 weeks, the left ventricular
wall thickness was greater in the combination group than in the stem cell therapy alone group (1.79  0.11 and
1.33  0.13, respectively, P ¼ .02).
Conclusions:Combining a cardiac support device with stem cell therapy preserves left ventricular function after
myocardial infarction, more than either therapy alone. Furthermore, stem cell delivery using a cardiac support
device is a novel delivery approach for cell-based therapies. (J Thorac Cardiovasc Surg 2010;140:1374-80)Heart failure is an epidemic affecting roughly 5 million
Americans annually. Despite the various pharmacologic
and therapeutic advances made in the treatment of ischemic
heart failure, the overall mortality remains high.1 Funda-
mentally, heart failure is characterized by the loss of
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The Journal of Thoracic and Cardiovascular Surventricle are known as ventricular remodeling. Promising
surgical and cell-based therapies are being developed to
target the start of ventricular remodeling, specifically
by treating the ischemic heart after myocardial infarction
(MI).MECHANICAL THERAPY
One specific feature of ventricular remodeling is the LV
dilation and an alteration in the orientation of the cardiac
muscle fibers.2 Surgical therapy for heart failure has been
developed to target the increased LV wall stress associated
with ventricular dilation. For example, in ventricular re-
straint therapy, a prosthetic material is surgically wrapped
around the heart to mechanically constrain the ventricles,
without restricting ventricular filling. By providing end-
diastolic support, ventricular restraint lowers myocardial
wall stress and cardiomyocyte overstretch. The data gener-
ated from the clinical and animal trials have indicated that
lowering myocardial wall stress reverses or halts the re-
modeling process.3,4 Subsequent work has further
demonstrated that in addition to decreasing ventricular
dilation, a substantial improvement in ejection fraction is
observed.5,6gery c December 2010
Abbreviations and Acronyms
EF ¼ ejection fraction
%FAC ¼ fractional area of change
FS ¼ fractional shortening
LV ¼ left ventricular
LVID ¼ LV internal diameter
MI ¼ myocardial infarction
MSC ¼ mesenchymal stem cell
Mokashi et al Evolving Technology/Basic ScienceCELLULAR THERAPY
Given the limited regenerative capacity of the heartmuscle,
the use of exogenous cells to replace lost or damaged
cardiomyocytes has enormous therapeutic potential for
postinfarction heart failure. Although the ideal cell subtype
for transplantation remains controversial, a particular interest
has developed in bone marrow-derived mesenchymal stem
cells (MSCs). MSCs are highly advantageous for use in
cellular therapy because they are readily isolated from adult
bone marrow, highly expandible ex vivo, and prevent T-cell
maturation. In effect, allogenicMSCs are not rejected by their
recipient host.7 Ideally,MSCswould replace the lost/damaged
cardiomyocytes. Nonetheless, despite conclusive evidence
that MSCs replace the lost cardiomyocytes, one beneficial
effect ofMSCsonLVdysfunction afterMIhas been attributed
to its paracrine effect on cardiomyocytes by secreting various
growth factors and cytokines, including granulocyte-
macrophage colony stimulating factors, stem cell factor 1,
and several interleukins.8,9 MSCs provide a unique approach
to improve LV function in ischemic heart disease.10,11E
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To our knowledge, the combination of ventricular re-
straint therapy and stem cell therapy (combination therapy)
in the setting of acute MI has not been previously studied.
We hypothesized that combining stem cell therapy and
ventricular restraint therapy will preserve cardiac function
after MI more than either therapy alone. Thus, we devel-
oped a strategy to target heart failure at the underlying
mechanical and cellular level. Accordingly, the aim of the
present study was to determine whether combination stem
cell-ventricular restraint therapy would preserve LV func-
tion in a rodent infarction model.MATERIALS AND METHODS
Animal Care
All rats received care in accordance with the guidelines of the ‘‘Guide
for the Care and Use of Laboratory Animals’’ published by the National
Institutes of Health (NIH publication No. 85-23, National Academy Press,
Washington, DC, revised 1996). Female Lewis rats (Charles River,
Wilmington, Mass) weighing 175 to 215 g were used in the present study
and housed in a Harvard Medical Area Standing Committee on Animals–
approved animal facility.The Journal of Thoracic and CarBone Marrow MSC Isolation, Expansion, and
Labeling
In brief, female Lewis rats were killed with an intraperitoneal injection
of sodium pentobarbital (100 mg/kg). The femur and tibia were removed
and flushed with cold phosphate-buffered saline. The bone marrow was
aspirated with a syringe containing phosphate-buffered saline with 10%
fetal bovine serum and 100 IU/mL heparin. To separate the bone marrow
cells from fat tissue, the solution was filtered through a 70-mm filter and
centrifuged twice to obtain a cell pellet, as described by Yablonka-
Reuveni and Nameroff.12 The pellet was resuspended with complete me-
dium, the cells were seeded with 8 mL/dish complete medium (Dulbecco’s
modified Eagles medium supplemented with 15% fetal bovine serum, 1%
penicillin, 50 mg/mL of ascorbic acid and 2.5 mL L-glutamine) and cul-
tured in 5% carbon dioxide, 90% humidity, and 37C. The cells were pas-
saged once until subconfluence was reached. To isolate the MSCs, at first
passage, the cells were labeled with green fluorescence protein, and the
green fluorescence protein-labeled MSCs were sorted by fluorescence-
activated cell sorting. On the third passage, the sorted MSCs were recul-
tured until confluence was reached and stored in liquid nitrogen until use.
Collaged-Based Scaffold for Cell Transplantation
In brief, MSCs (stored in liquid nitrogen) were thawed. After confluence
was reached, cultured cells were dissociated from the culture dishes with
0.05% trypsin (Gibco BRL, Grand Island, NY) in phosphate-buffered sa-
line, neutralized withmedium, and centrifuged at 2000 rpm for 5minutes at
4C, as described by Tomita and colleagues.13 After centrifugation, the cell
pellet was resuspended in culture medium at a concentration of 53 105. A
50-mL cell suspension was used for each scaffold. The scaffolds were made
from chondroitin-6-sulfate and had an average pore size of 96 12 mm and
99.5% porosity; 25 mL was loaded on each side of a collagen-based scaf-
fold (5 loading points/side), and the scaffold was stored in medium at 37C
for 24 hours before use. Square-shaped scaffolds (1.0 cm 3 1.0 cm), with
an average pore diameter of 96  12 mm of 100 mm and 99.5% porosity,
were prepared from chondroitin-6-sulfatecross-linked according to a
freeze-dry technique.
Ventricular Restraint Device
The ventricular restraint device used in the present study was a thin plas-
tic sheet wrapped around both ventricles to provide end-diastolic support.
The wrap was surgically positioned snugly around both ventricles from the
apex to the atrioventricular groove. Each wrap was placed by a single
surgeon to provide support without compromising filling and to provide
standardization of the wrap placement.
MI Model
Each surgical procedure was performed by 1 animal surgeon with
extensive experience in rodent surgery. An established and highly repro-
ducible rodent model of MI was used.14 In brief, the rats were anesthetized
using pentobarbital sodium (50 mg/kg intraperitoneally), intubated with
a 14-guage angiocatheter and mechanically ventilated with positive-
pressure ventilation. Standard midline sternotomy and pericardiotomy
was performed, and the left coronary artery was identified and ligated
with a 6-0 polypropylene suture (Ethicon, Johnson & Johnson Somerville,
NJ) near its origin. The anterior wall of the left ventricle was observed for
evidence of blanching, indicating ischemia. If the myocardium did not be-
come increasingly pale, a second ligature was placed more proximally, un-
til a large anterolateral MI comprising approximately 30% of the left
ventricle was noted.
Treatment Groups
Each rat was randomized into 4 treatment groups: MI, MI and ventric-
ular restraint therapy, MI and stem cell therapy, and MI and combination
ventricular restraint-stem cell therapy (Figure 1).diovascular Surgery c Volume 140, Number 6 1375
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FIGURE 1. Schematic representation of treatment groups. A, Control group; B, stem cell therapy group; C, ventricular restraint group; and D, combination
ventricular restraint-stem cell therapy group.
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After the MI had been confirmed, the surgeon was informed of the treat-
ment group the rat had been randomly assigned to. In the control group, the
chest was immediately closed in layers. In the ventricular restraint group,
the ventricular restraint devicewas wrapped around the heart with 5-0 poly-
propylene purse-string suture (Ethicon, Johnson & Johnson) to attain
a snug fit, without compromising the ventricular function (Figure 1). In
the stem cell group, the MSC-seeded scaffold was sutured to the left ven-
tricle using 6-0 polypropolyene suture at each corner of the scaffold (John-
son & Johnson; Figure 1). For the combination therapy group (stem cell-
ventricular restraint therapy), the stem cell-seeded scaffold was sutured
to the left ventricle with 6-0 polypropolyene suture, followed by placement
of the ventricular restraint device (Figure 1). In each rat, the muscle layer
and skin incisionwere closed with 3-0 silk sutures. The rats were monitored
for 4 hours postoperatively.
Four treatment groups were MI group (n ¼ 6), stem cell therapy group
(n ¼ 5), ventricular restraint therapy group (n ¼ 8), and combination stem
cell therapy ventricular restraint therapy group (n ¼ 5).
Echocardiography
Transthoracic echocardiography was performed by a separate, blinded
investigator on all rats at baseline (1 week before surgery) and 2, 4, and
6 weeks after surgery. A commercially available echocardiographic system
equipped with a 30-MHz phased-array transducter was used (VisualSonic
Vevo 770, Ontario, Canada). A 2-dimensional mode in the short-axis view
of the left ventricle at the level of the papillary muscle was obtained and
used to record the M-mode tracings.
The following variables were measured: LV posterior wall thickness,
LV internal diameter (LVID), interventricular septum thickness, fractional
area of change, fractional shortening (FS), and ejection fraction (EF). All
measurements were averaged for three cardiac cycles and were performed
by an experienced technician blind to the treatment group.
Histologic and End of Life Analysis
At 6 weeks after surgery, the rats were killed with pentobarbital (50 mg/
kg). The hearts were quickly excised and perfused with Krebs-Henseleit
buffer (mmol/L:NaCl, 118; KCl, 4.7; KH2PO4, 1.2; CaCl2, 2.5; MgSO4,1376 The Journal of Thoracic and Cardiovascular Sur1.2; NaHCO3, 25; and glucose, 11; pH 7.4) followed by fixation with neu-
tralized 10% formaldehyde. Each heart was weighed, tibia length mea-
sured and liver/lung wet and dry weight (48 hours of dehydrating) were
measured.
The left ventricle was cut transversely from base to apex into 4 equal
regions—5-mm slices of each regionwere embedded in paraffin and stained
with hematoxylin and eosin and Masson’s trichrome.
Infarct Percentage Analysis
Hematoxylin and eosin-stained sections were analyzed for infarct per-
centage analysis. The epicardial and endocardial surface areas of each sec-
tion were measured by the techniques of Pfeffer and colleagues.15 The
epicardial and endocardial circumference, and circumference occupied
by the infracted wall were traced onto a transparency and quantified using
digital planimetry software in a blinded manner. Infarct size was expressed
as percentage of the total LV circumference.
Statistic Analysis
Data are given as the mean standard error. To compare the echocardio-
graphic parameters over time between treatment groups, we used a version
of repeated measures analysis of variance that accounts for the correlation
within subjects using an autoregressive correlation model (SAS PROC
MIXED, SAS Institute, Cary, NC). To compare echocardiographic param-
eters at a given time between treatment groups, we used a t test derived
from the same repeated measures analysis of variance. To compare echocar-
diographic parameters from baseline to 6 weeks within each group, we used
a paired t test. Differences were considered significant at P  .05.
Responsibility
The authors had full access to the data and take full responsibility for
their integrity. All authors have read and agree to the report as written.RESULTS
Of the 60 rodents that underwent a MI/therapeutic inter-
vention procedure, 24 survived and were included in the
analysis.gery c December 2010
FIGURE2. Evidence of effectivemesenchymal stem cell transplantation at 72 hours after transplant. In vivo characterization of A, mesenchymal stem cells
(MSCs) on stem cell scaffold positioned on infarcted myocardium and B, MSCs translocated within infracted myocardium. Paraffin-embedded slides
underwent immunofluorescence staining with antibodies 460-diamidino-2-phenylindole-2 HCl and anti-green fluorescence protein.
FIGURE 3. Percentage of left ventricular infarction area. A, Histologic
examination of percentage of left ventricular (LV) infarction by trichrome
staining. Quantitative analysis showed 5% lower LV infarction percentage
in combination therapy group compared with control group (P ¼ .39).
C, control; S, stem cell; VR, ventricular restraint; SC-VR, stem cell-
ventricular restraint. Representative samples from typical left ventricle
divided into 4-equal sections from base to apex from B, Stem cell therapy
group and C, ventricular restraint group. Blue region represents area of
infarction.
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To confirm that MSCs were effectively loaded on a colla-
gen-based scaffold and transplanted within the ischemic
myocardium, paraffin-embedded hearts were immunohisto-
chemically stainedwith monoclonal antibodies against anti-
green fluorescence protein and diamidino-2-phenylindole.
The maximal number of MSCs was found concentrated in
the middle of the collagen-based scaffold (Figure 2, A)
and had successfully been translocated within the ischemic
myocardium after transplantation (Figure 2, B).
Infarction Percentage
The percentage of LV infarction area was appropriately
equivalent in the combination group compared with the
control group at 6 weeks (26%  12% versus 31% 
6%, P ¼ 0.39, Figure 3, A). Furthermore, in the stem cell
group, the percentage of LV infarction was identical to the
control group (32%  8% versus 31%  6%, P ¼ .39).
This implies that any functional/morphologic differences
observed among the treatment groups could not be attrib-
uted to a difference in infarction size. A representative LV
sectioned into 4 segments from apex to base and stained
with hematoxylin and eosin is illustrated in Figure 3, B.
The ventricular segment that stained blue represents the in-
farction area.
LV Morphologic Assessment
Cardiac morphology was studied according to the LV
chamber size (LVID) and LV wall thickness (average of
LV posterior wall and interventricular septum at diastole),
which was determined by echocardiography. At 6 weeks,
the LVID was less in the stem cell group compared with
the control (6.2  1.3 mm versus 7.2  0.8 mm). The
LVID was equal between the control, restraint group, and
combination groups (7.2%  0.8% versus 7.7%  1.1%The Journal of Thoracic and Carversus 7.3%  0.9%). Regarding wall thickness, at 6
weeks, the LV wall thickness was greater with combination
group (1.8  0.3) compared with stem cell group alone
(1.4  0.2) (P ¼ .02).diovascular Surgery c Volume 140, Number 6 1377
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FIGURE 4. A, Ejection fraction (EF) and B, fractional shortening (FS) as a function of time. Values expressed as mean of each treatment group at specific
time. C, control; SC, stem cell; VR, ventricular restraint; SC-VR, stem cell-ventricular restraint. Values expressed as mean  standard error.
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At baseline, the ejection fraction (EF), fractional shorten-
ing (FS), and fractional area change (%FAC) at the mid-
papillary level were similar among each treatment group.
At 2 weeks afterMI and intervention, a mean absolute de-
crease in EF from baseline was observed in the control
group (Figure 4, A). In contrast, the EF was preserved in
the combination group (baseline 80.2%%  2.7% versus
2 weeks, 74.9% 5.6%, P¼ NS, Figure 4, A). At 2 weeks
after infarction, a large difference was seen in the percent-
age decrease in EF from baseline in the control and combi-
nation groups (20.0% versus 6.6%).
From 2 to 4 weeks afterMI and intervention, the EF in the
control group did not change and remained decreased
(66.2%  15% versus 65.4%  15.4%, Figure 4, A).
Appropriately, the EF in the combination group remained
the same; however, this effect was beneficial because the
EF was preserved (74.9%  8.9% versus 70.5% 
6.1%, Figure 4, A). By 6 weeks after MI, the EF was similar
between the control and combination group (63.7% 
3.4% versus 69.1%  4.2%, P ¼ .35). However, a statisti-
cally significant difference was seen in the%FAC between
the control (69.2%  6.7%) and combination group
(49.5%  6.1%; P ¼ .04).
At 2, 4, and 6 weeks, the EF, FS, and%FAC were greater
in the combination group than in the stem cell group itself.
Moreover, the EF of the combination group and restraint
group were similar at 4 and 6 weeks (70.5% 3.7% versus
72.4%  3.0%, P ¼ .72 and 69.1%  6.0% versus
67.6%  4.3%, P ¼ .8, respectively).1378 The Journal of Thoracic and Cardiovascular SurEnd of Life Analysis
To assess the systemic response to heart failure, the heart,
left ventricle, tibia length ratio, and liver/lung wet/dry
weights were measured. At the end of life inspection, the
hearts from the various treatment groups were indistin-
guishable from the control MI group. The LV weight, heart
weight/tibia length, and heart weight/body weight were
identical in all groups. Moreover, the change in both the
lung and liver at 48 hours, the wet/dry ratio were similar
in all groups.
DISCUSSION
Stem cell therapy and ventricular restraint therapy have
each been shown to improve ventricular function in clinical
and animal heart failure models, suggesting, at least in part,
that each reverses the remodeling process. However, com-
bining the 2 therapies had yet to be studied. We have shown
that combination stem cell-ventricular restraint therapy pre-
serves cardiac function after MI. In addition, ventricular
restraint attenuates the beneficial functional and morpho-
logic effects of stem cell therapy. Combination stem cell-
ventricular restraint therapy preserved the wall thickness
more than stem cell therapy alone.
Heart failure is regarded as an irreversible and progres-
sive disease marked by ventricular enlargement, mechani-
cal insufficiency, and pump dysfunction. The initial insult
to pump function evokes compensatory mechanisms aimed
at maintaining cardiac output—ventricular dilation, cardio-
myocyte hypertrophy, and neurohumoral activation.16
Although early on the compensatory response preservesgery c December 2010
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process results in deleterious LV structural and functional
changes—ventricular remodeling. Ultimately, end-stage
disease develops and the heart is unable to maintain
systemic perfusion required for metabolizing tissues. Spe-
cifically, ventricular remodeling is characterized by an
alteration in LV function and structure—involving both
the infarcted and the noninfarcted ventricular topography.
Several pathologic processes contribute to LV dilation: thin-
ning and lengthening of infarct and border zone regions
(infarct expansion), myocardial wall stress, and infarct heal-
ing. These multiple factors contributed at different stages,
from the point of infarction until the development of
ventricular dilation. Pfeffer and colleagues17 proved that
the most effective method to prevent or minimize ventricu-
lar remodeling after MI is to limit the initial insult.18
Accordingly, our laboratory has developed a therapeutic
intervention to halt ventricular remodeling at its inception,
by treating the ischemic heart with both cellular and
mechanical-based therapy.
The present study has demonstrated that combination
therapy beneficially preserves cardiac function after MI.
The combination group had greater EF, FS, and %FAC at
2, 4, and 6 weeks after myocardial ischemia compared
with the control group. However, the findings at 6 weeks
warrant discussion. The LVID was similar between the
combination and control groups. One possible explanation
is that a paracrine effect from the MSCs was short lived.
As suggested by Dai and colleagues,19 the beneficial effects
of stem cell therapy on the cardiac structure might not
be apparent by 6 weeks. The goal of cellular therapy—to
regenerate lost myocardium through the differentiation of
stem cells into cardiomyocytes, might take longer than
expected. Their results have shown that of the transplanted
MSCs that survived in infarcts, the expression of muscle
markers required up to 6 months.19 This was further sup-
ported by Davani and colleagues,20 who noted that MSCs
fail to express major gap junction proteins of the interca-
lated disks of cardiomyocytes at 6 weeks. This provides
additional evidence that terminal differentiation of MSCs
might require long periods.20 At the 4- and 6-week points,
the EF of the restraint device was similar to the combination
group, further supporting a potential paracrine effect role of
the MSCs. Moreover, no difference was found in the infarct
percentage area in the groups with MSCs.
At present, the exact window of treatment to prevent or
reverse the remodeling process is unknown. The timing
and route of stem cell administration to the infracted myo-
cardium are important variables for successful cellular ther-
apy. We believe the direct application of MSCs to the
infracted and border zone areas of the myocardium provides
an optimal route for cell transplantation. Hale and col-
leagues21 compared MSC survival when transplanted im-
mediately after MI using either intravenous administrationThe Journal of Thoracic and Caror direct myocardial injection to the infarction. The investi-
gators had shown that 15% of labeled cells remained in the
left ventricle 1 week after direct myocardial injection com-
pared with<1% after intravenous injection. Furthermore,
although MSC transplantation has shown a benefit after
acute MI, the optimal timing for therapeutic intervention
is unknown.22 Using a rodent MI model, Jiang and col-
leagues23 compared the effects of MSC transplantation at
1 hour, 1 week, and 2 weeks. They found that MSC trans-
plantation at 1 week compared with 1 hour showed an
improvement in cardiac function (FS and EF), apoptosis,
and angiogenesis.23 We have, therefore, concluded direct
stem cell transplantation using a scaffold provides an effec-
tive delivery method, although the optimal timing remains
unknown.
At 2 weeks after MI and therapeutic intervention, a clear
functional advantage existed in the combination stem cell-
ventricular restraint therapy group compared with the con-
trol group. However, this beneficial effect became less clear
by 6 weeks. One possibility was that the stem cells became
damaged by 6 weeks. To preserve stem cell function, as sug-
gested by Davis and colleagues,24 an optimal stem cell mi-
croenvironment should be used that promotes cell survival
and organization. Specifically, a peptide-based scaffold
can be engineered to minimize the profound inflammatory
response after MI and also produce beneficial growth
factors/signals for cardiomyocyte recruitment.24
One surprising finding in the present study was the ben-
eficial effect of ventricular restraint on cellular therapy. In
terms of EF, FS, and endocardial area change, the rats
treated with combination therapy showed a greater im-
provement in each of the 3 parameters compared with
stem cell therapy alone. Therefore, ventricular restraint im-
proves the effectiveness of stem cell therapy. Future studies
determining the exact mechanism of combination therapy
are needed.
In ventricular restraint therapy, a prosthetic wrap provides
circumferential diastolic support, thereby preventing adverse
ventricular remodeling.Once implanted, thewrap is constant
and unchanging, even as the heart undergoes reverse remod-
eling. Consequently, no rational criteria exist to optimize
therapy in a physiologicmanner (i.e., nowaymethod is avail-
able to maintain a constant level of restraint even as the size
of the heart decreases and the wrap becomes effectively
looser). We believe that this nonmeasurable and nonadjusta-
ble nature of current devices is the greatest limitation of cur-
rent restraint technology. Our laboratory therefore developed
an adjustable, fluid-filled polyurethane balloon capable of
quantitatively applying restraint to the entire ventricular sur-
face.3 We then showed that the application of this device to
both ventricles with periodic adjustments to maintain the
level of restraint was associated with significant reductions
in end-diastolic volume and increases in EF in an ovine
model of heart failure.3 These changes were associateddiovascular Surgery c Volume 140, Number 6 1379
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gen consumption, providing a theoretical basis for how ven-
tricular restraint produces reverse LV remodeling in heart
failure. Although difficult to use in a rodent model, future
studies with adjustable ventricular restraint in a large animal
model of cardiomyopathy are needed.
A second limitation was that although 60 rats underwent
the MI/treatment intervention, 24 rats survived the opera-
tion. The overall number of rats per group could have led
to a bias in our conclusion. However, the overall trend dif-
ferences in morphology and function between the treatment
groups are apparent.
Treating heart failure presents a daunting challenge
for cardiovascular specialists. Current therapeutic strate-
gies have focused on either stem cell therapy or mechan-
ical (ventricular restraint therapy). However, any truly
successful treatment plan must address the underlying
problem—cellular death/dysfunction and altered ventricu-
lar mechanics—or the effectiveness will ultimately be
inadequate.CONCLUSIONS
The results of the present study have demonstrated the
therapeutic potential of combining stem cell therapy with
ventricular restraint therapy.References
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